Innofem

Innofem Overview

Updated: 

Innofem is a prescription medication used to treat symptoms of menopause including hot flashes and vaginal dryness. 

Innofem consists of estradiol which is a form of the hormone estrogen. It replaces estrogen that is not naturally produced by the ovaries.

This medication comes is available as an an oral tablet. It is usually taken once a day, with food.

Common side effects include headache, breast pain, nausea, and bloating.

Patient Ratings for Innofem

How was your experience with Innofem?

First, a little about yourself

Tell us about yourself in a few words?

What tips would you provide a friend before taking Innofem?

What are you taking Innofem for?

Choose one
  • Other
  • Hot Flashes
  • Hypogonadism
  • Menopause, Premature
  • Menorrhagia
  • Osteoporosis, Postmenopausal
  • Primary Ovarian Insufficiency
  • Prostatic Neoplasms

How long have you been taking it?

Choose one
  • Less than a week
  • A couple weeks
  • A month or so
  • A few months
  • A year or so
  • Two years or more

How well did Innofem work for you?

Did you experience many side effects while taking this drug?

How likely would you be to recommend Innofem to a friend?

Innofem Cautionary Labels

precautions

Manufacturer

Innofem Drug Class

Innofem is part of the drug class:

Innofem FDA Warning

WARNING: ESTROGENS INCREASE THE RISK OF ENDOMETRIAL CANCER.

CLOSE CLINICAL SURVEILLANCE OF ALL WOMEN TAKING ESTROGENS IS IMPORTANT. ADEQUATE DIAGNOSTIC MEASURES, INCLUDING ENDOMETRIAL SAMPLING WHEN INDICATED, SHOULD BE UNDERTAKEN TO RULE OUT MALIGNANCY IN ALL CASES OF UNDIAGNOSED PERSISTENT OR RECURRING ABNORMAL VAGINAL BLEEDING. THERE IS CURRENTLY NO EVIDENCE THAT THE USE OF “NATURAL” ESTROGENS RESULTS IN A DIFFERENT ENDOMETRIAL RISK PROFILE THAN SYNTHETIC ESTROGENS OF EQUIVALENT ESTROGEN DOSE.

CARDIOVASCULAR AND OTHER RISKS 

ESTROGENS WITH AND WITHOUT PROGESTINS SHOULD NOT BE USED FOR THE PREVENTION OF CARDIOVASCULAR DISEASE OR DEMENTIA.

THE WOMEN’S HEALTH INITIATIVE (WHI) STUDY REPORTED INCREASED RISKS OF MYOCARDIAL INFARCTION, STROKE, INVASIVE BREAST CANCER, PULMONARY EMBOLI, AND DEEP VEIN THROMBOSIS IN POSTMENOPAUSAL WOMEN (50 TO 79 YEARS OF AGE) DURING 5 YEARS OF TREATMENT WITH ORAL CONJUGATED ESTROGENS (CE 0.625 MG) COMBINED WITH MEDROXYPROGESTERONE ACETATE (MPA 2.5 MG) RELATIVE TO PLACEBO.

THE WOMEN’S HEALTH INITIATIVE MEMORY STUDY (WHIMS), A SUBSTUDY OF WHI, REPORTED INCREASED RISK OF DEVELOPING PROBABLE DEMENTIA IN POSTMENOPAUSAL WOMEN 65 YEARS OF AGE OR OLDER DURING 4 YEARS OF TREATMENT WITH ORAL CONJUGATED ESTROGENS PLUS MEDROXYPROGESTERONE ACETATE RELATIVE TO PLACEBO. IT IS UNKNOWN WHETHER THIS FINDING APPLIES TO YOUNGER POSTMENOPAUSAL WOMEN.

OTHER DOSES OF ORAL CONJUGATED ESTROGENS WITH MEDROXYPROGESTERONE ACETATE, AND OTHER COMBINATIONS AND DOSAGE FORMS OF ESTROGENS AND PROGESTINS WERE NOT STUDIED IN THE WHI CLINICAL TRIALS AND, IN THE ABSENCE OF COMPARABLE DATA, THESE RISKS SHOULD BE ASSUMED TO BE SIMILAR. BECAUSE OF THESE RISKS, ESTROGENS WITH OR WITHOUT PROGESTINS SHOULD BE PRESCRIBED AT THE LOWEST EFFECTIVE DOSES AND FOR THE SHORTEST DURATION CONSISTENT WITH TREATMENT GOALS AND RISKS FOR THE INDIVIDUAL WOMAN.